Cochlear Ltd
Company Profile
Business description
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
Contact
1 University Avenue
Macquarie University
SydneyNSW2109
AUST: +61 294286555
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2027
Employees
5,500
Cochlear Ltd News & Analysis
markets
The grass is always greener: Rethinking Australian vs global equities
stocks
Wide moat healthcare leader remains undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,297.10 | 15.10 | 0.16% |
| CAC 40 | 8,636.80 | 13.76 | -0.16% |
| DAX 40 | 26,440.31 | 140.57 | 0.53% |
| Dow JONES (US) | 53,732.41 | 107.58 | -0.20% |
| FTSE 100 | 10,750.11 | 22.56 | -0.21% |
| HKSE | 25,519.83 | 402.98 | 1.60% |
| NASDAQ | 26,729.16 | 73.86 | -0.28% |
| Nikkei 225 | 68,721.44 | 7.64 | 0.01% |
| NZX 50 Index | 13,792.31 | 62.07 | -0.45% |
| S&P 500 | 7,785.76 | 13.23 | -0.17% |
| S&P/ASX 200 | 9,091.50 | 12.20 | 0.13% |
| SSE Composite Index | 3,946.47 | 19.30 | 0.49% |